Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)

NCT02148718 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02148718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02148718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2014
Completion date
January 31, 2017
Enrollment
100 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe crohn's disease